The '''pharmaceutical industry in the United Kingdom''' directly employs around 72,000 people and in 2007 contributed £8.4 billion to the UK's [[GDP]] and invested a total of £3.9 billion in [[research and development]].<ref>{{cite web|url=http://www.abpi.org.uk/our-work/library/industry/Documents/Did%20you%20know_Jan11.pdf|title=Did you know?: Facts and figures about the pharmaceutical industry in the UK - Second edition 2011|publisher=The Association of the British Pharmaceutical Industry|accessdate=13 May 2011}}</ref><ref>{{cite news|url=http://business.timesonline.co.uk/tol/business/industry_sectors/health/article5594350.ece|title=Gordon Brown plans tonic for pharmaceutical industry|accessdate=27 October 2010|publisher=The Times|date=27 January 2009}}</ref> In 2007 exports of pharmaceutical products from the UK totalled £14.6 billion, creating a trade surplus in pharmaceutical products of £4.3 billion.<ref>{{cite web|url=http://www.abpi.org.uk/statistics/intro.asp|title=Facts & Statistics from the pharmaceutical industry|publisher=The Association of the British Pharmaceutical Industry|accessdate=27 October 2010}}</ref> 

The UK is home to [[GlaxoSmithKline]] and  [[AstraZeneca]], respectively the world's fifth- and sixth-largest pharmaceutical companies measured by 2009 market share.<ref>{{cite web|url=http://www.abpi.org.uk/industry-info/knowledge-hub/global-industry/Pages/pharmaceutical-companies.aspx|title=Top world pharmaceutical corporations|publisher=The Association of the British Pharmaceutical Industry|accessdate=13 May 2011}}</ref> Foreign companies with a major presence in the UK pharmaceutical industry include [[Pfizer]], [[Novartis]],<ref>{{cite web|url=http://www.novartis.co.uk/about/facts_figures.shtml|title=Facts and Figures|publisher=Novartis UK|accessdate=27 October 2010}}</ref> [[Hoffmann–La Roche]] and [[Eisai (company)|Eisai]]. One in five of the world's biggest-selling prescription drugs were developed in the UK.<ref name=iht>{{cite news|url=http://www.nytimes.com/2007/02/20/business/worldbusiness/20iht-price.4663653.html|title=British regulator calls for drug pricing overhaul|accessdate=27 October 2010|publisher=International Herald Tribune|date=27 January 2009}}</ref>

==History==
{{Expand section|year=2011|date=March 2011}}
[[File:BeechamsBuilding.jpg|thumb|right|Beecham's Clock Tower, constructed in 1877 as part of the [[Beecham (pharmaceutical company)|Beecham]] factory in [[St Helens, Merseyside|St Helens]]]]

===19th century===

In 1842 [[Thomas Beecham (chemist)|Thomas Beecham]] established the [[Beecham's Pills]] laxative business, which would later become the [[Beecham Group]].<ref name=tbeech>{{cite news|url=http://news.bbc.co.uk/1/hi/business/59523.stm|title=Drug giants in their own right|accessdate=13 May 2011|publisher=BBC News|date=24 February 1998 }}</ref> By 1851 UK-based patent medicine companies had combined domestic revenues of around £250,000.<ref name=pharmindguid>{{citation |url=http://books.google.co.uk/books?id=4JYjsQkBm3MC&dq=%22Drug+Club%22+1891&source=gbs_navlinks_s|title=The pharmaceutical industry: a guide to historical records|author=Lesley Richmond, Julie Stevenson, Alison Turton| publisher=Ashgate Publishing| location=London, UK | year=2003| isbn=0-7546-3352-7, 9780754633525 | accessdate=25 May 2011}}</ref> Beecham opened Britain's first modern drugs factory in [[St Helens, Merseyside|St Helens]] in 1859.<ref name=tbeech/> [[Henry Wellcome]] and [[Silas Mainville Burroughs, Jr.|Silas Burroughs]] formed a partnership in September 1880, and established an office in Snow Hill in Central London.<ref name=wth>{{cite web|url=http://www.wellcome.ac.uk/About-us/History/WTX051562.htm|title=The birth and growth of Burroughs Wellcome & Co.|publisher=Wellcome Trust|accessdate=13 May 2011}}</ref> The London Wholesale Drug and Chemical Protection Society was formed in 1867, which became the Drug Club in 1891, the forerunner of the present-day [[Association of the British Pharmaceutical Industry]].<ref name=pharmindguid/> In 1883 Burroughs Wellcome & Co. opened their first factory, at Bell Lane Wharf in [[Wandsworth]], utilising compressed medicine tablet-making machinery acquired from [[Wyeth]] of the United States.<ref name=wth/> Burroughs Wellcome & Co. established its first overseas branch in Sydney in 1898.<ref name=wth/>

===20th century===

The Glaxo department of Joseph Nathan and Co was established in London in 1908.<ref name=gskhist>{{cite web|url=http://www.gsk.com/about/history.htm|title=Our history|publisher=GlaxoSmithKline plc|accessdate=13 May 2011}}</ref> Glaxo Laboratories Ltd absorbed Joseph Nathan and Co in 1947 and was listed on the London Stock Exchange in the same year.<ref name=gskhist/> In order to satisfy regulations then in place in the UK on the importation of medicines, [[Pfizer]] established a compounding operation in [[Folkstone]], Kent in Autumn 1952.<ref name=history1>{{cite web|url=http://www.pfizer.co.uk/sites/PfizerCoUK/AboutUs/History/Pages/PfizerWorldwide.aspx|title=Pfizer's history 1949-55|accessdate=25 November 2010|publisher=Pfizer UK}}</ref> Pfizer acquired an 80 acre site on the outskirts of [[Sandwich, Kent|Sandwich]] in 1954 to enable the expansion of its Kent-based activities.<ref name=history1/> Glaxo acquired [[Allen & Hanburys|Allen and Hanburys Ltd.]] in 1958.<ref name=gskhist/> In 1981 the bacterial infection treatment Augmentin ([[Amoxicillin|amoxicillin/clavulanate potassium]]) was launched by Beecham; the anti-ulcer treatment Zantac ([[ranitidine]]) was launched by Glaxo; and the antiviral herpes treatment Zovirax ([[aciclovir]]) was launched by Wellcome.<ref name=gskhist/> 

In 1991 SmithKline Beecham launched Seroxat/Paxil ([[Paroxetine|paroxetine hydrochloride]]).<ref name=gskhist/> In June 1993 [[Imperial Chemical Industries]] demerged its pharmaceuticals and [[agrochemicals]] businesses, forming [[Zeneca|Zeneca Group plc]].<ref>{{cite web|url=http://www.astrazeneca.com/About-Us/History/Merger-partners-in-brief|title=Merger partners in brief|publisher=AstraZeneca plc|accessdate=1 February 2011}}</ref> In 1995 Glaxo opened a major research and development facility in [[Stevenage]], constructed at a cost of £700 million.<ref>{{cite news|url=http://www.independent.co.uk/news/business/ministers-fear-glaxo-merger-could-damage-drug-industry-1143870.html|title=Ministers fear Glaxo merger could damage drug industry|accessdate=13 May 2011|publisher=The Independent|date=9 February 1998}}</ref> In March 1995 the £9 billion acquisition of Wellcome by Glaxo was completed, forming [[Glaxo Wellcome]], in what was the largest merger in UK corporate history to date.<ref>{{cite news|url=http://news.bbc.co.uk/1/hi/business/606752.stm|title=Profile: Glaxo Wellcome|accessdate=13 May 2011|publisher=BBC News|date=17 January 2000}}</ref> [[BASF]] completed the acquisition of the pharmaceutical division of [[Boots UK|The Boots Company]] in April 1995.<ref>{{cite news|url=http://www.nytimes.com/1997/05/19/us/lawsuit-says-companies-suppressed-drug-study.html|title=Lawsuit Says Companies Suppressed Drug Study|accessdate=14 May 2011|publisher=The New York Times|date=19 May 1997}}</ref> In 1997 SmithKline Beecham opened a major new research centre at New Frontiers Science Park in [[Harlow]], [[Essex]].<ref name=gskhist/> In 1999 Zeneca Group plc and Sweden-based [[Astra AB]] merged to form AstraZeneca plc.<ref>{{cite web|url=http://www.astrazeneca.com/About-Us/History|title=History|publisher=AstraZeneca plc|accessdate=1 February 2011}}</ref> Glaxo Wellcome and SmithKline Beecham announced their intention to merge in January 2000, with the merger completing in December of that year, forming GlaxoSmithKline plc.<ref>{{cite news|url=http://www.telegraph.co.uk/finance/4476425/Pharmaceutical-giants-Glaxo-and-SmithKline-finally-merge.html|title=Pharmaceutical giants Glaxo and SmithKline finally merge|accessdate=1 February 2011|publisher=Reuters| date=27 December 2000}}</ref>

===21st century===

In February 2001 the Novartis Respiratory Research Centre, the largest single-site respiratory research centre in the world, opened in Horsham.<ref>{{cite news|url=http://www.chemeurope.com/en/news/1577/novartis-opens-the-world-s-largest-centre-for-respiratory-research-in-horsham-uk.html|title=Novartis opens the world's largest centre for respiratory research in Horsham, UK|accessdate=13 May 2011|publisher=Chem Europe|date=28 February 2001}}</ref> In May 2006 AstraZeneca agreed to buy [[Cambridge Antibody Technology]], then the largest UK-based biotechnology company, for £702 million.<ref>{{cite news|url=http://www.independent.co.uk/news/business/news/astrazeneca-pays-high-price-to-fill-drugs-chest-with-163700m-cat-deal-478434.html|title=AstraZeneca pays high price to fill drugs chest with £700m CAT deal|accessdate=13 May 2011|publisher=The Independent|date= 16 May 2006}}</ref><ref>{{cite news|url=http://www.timesonline.co.uk/tol/life_and_style/health/article718413.ece|title=AstraZeneca agrees £702m Cambridge deal|accessdate=13 May 2011|publisher=The Times|date= 15 May 2006}}</ref> In April 2007 AstraZeneca agreed to acquire the U.S.-based biotechnology company [[MedImmune]] for $15.6 billion.<ref>{{cite news|url=http://uk.reuters.com/article/2007/04/23/uk-medimmune-astrazeneca-idUKN2221194520070423|title=AstraZeneca agrees to buy MedImmune|accessdate=13 May 2011|publisher=Reuters|date=23 April 2007}}</ref> In April 2009 GlaxoSmithKline agreed to acquire [[Stiefel Laboratories]], then the world's largest independent dermatology company, for US$3.6 billion.<ref>{{cite news|url=http://www.telegraph.co.uk/finance/newsbysector/epic/gsk/5186751/GlaxoSmithKline-buys-Stiefel-for-3.6bn.html|title=GlaxoSmithKline buys Stiefel for $3.6bn |accessdate=25 May 2011|publisher=The Telegraph| date=20 April 2009}}</ref> In June 2009 [[Eisai (company)|Eisai]] opened a major new research and development and manufacturing facility in [[Hatfield, Hertfordshire|Hatfield]], constructed at a cost of over £100 million.<ref>{{cite news|url=http://news.bbc.co.uk/1/hi/england/beds/bucks/herts/6422947.stm|title=Work starts on £100m drug firm HQ|accessdate=13 May 2011|publisher=BBC News|date=6 March 2007}}</ref><ref>{{cite news|url=http://www.stalbansreview.co.uk/news/4460807.Terry_Pratchett_in_Hatfield_today/|title=Author backing Alzheimer's research|accessdate=13 May 2011|publisher=St Albans & Harpenden Review|date=26 June 2009}}</ref><ref>{{cite web|url=http://www.eisai.co.uk/307/Eisai-opens-European-Knowledge-Centre|title=European Knowledge Centre|publisher=Eisai Co., Ltd.|accessdate=13 May 2011}}</ref> In November 2009 GlaxoSmithKline and Pfizer combined their respective [[AIDS]] divisions into one London-based company, [[ViiV Healthcare]].<ref>{{cite news|url=http://www.nytimes.com/2009/11/10/health/10glob.html?_r=2&scp=1&sq=ViiV&st=cse|title=AIDS Divisions of 2 Large Drug Makers Form Company to Focus on the Disease|accessdate=1 February 2011|publisher=The New York Times| date=9 November 2009}}</ref> On 1 February 2011 Pfizer announced that it would be closing its entire research and development facility at [[Sandwich, Kent|Sandwich]], [[Kent]] within 18–24 months with the loss of 2,400 jobs, as part of a company-wide plan to reduce its spending on research and development.<ref>{{cite news|url=http://www.kentonline.co.uk/kentonline/news/2011/february/1/drug_giant_to_pull_out_of_kent.aspx|title=Drug giant Pfizer to pull out of Kent|accessdate=1 February 2011|publisher=Kent Online| date=1 February 2011}}</ref><ref>{{cite news|url=http://uk.reuters.com/article/2011/02/01/uk-pfizer-sandwich-idUKTRE7103TG20110201|title=Pfizer to shut major Sandwich site, home of Viagra|accessdate=1 February 2011|publisher=Reuters| date=1 February 2011}}</ref><ref>{{cite news|url=http://blogs.nature.com/news/thegreatbeyond/2011/02/thousands_of_jobs_to_go_as_pfi.html|title=Thousands of jobs to go as Pfizer looks to slash R&D spend|accessdate=1 February 2011|publisher=Nature| date=1 February 2011}}</ref>

In March 2013 AstraZeneca announced plans for a major corporate restructuring, including the closure of its research and development activities at Alderley Park, investment of $500 million in the construction of a new research and development facility in Cambridge, and the move of its corporate headquarters from London to Cambridge in 2016.<ref>{{cite news|url=http://uk.reuters.com/article/2013/03/18/uk-astrazeneca-rd-idUKBRE92H0I320130318|title=AstraZeneca to axe 1,600 jobs in overhaul of drug R&D|accessdate=23 March 2013|publisher=Reuters| date=18 March 2013}}</ref><ref>{{cite news|url=http://www.timeshighereducation.co.uk/news/astrazeneca-cuts-uk-headcount-and-moves-to-cambridge/2002642.article|title=AstraZeneca cuts UK headcount and moves to Cambridge|accessdate=23 March 2013|publisher=Times Higher Education| date=19 March 2013}}</ref>

==Research and development==
[[File:GlaxoSmithKline headquaters -Brentford, London, England-2Oct2011.jpg|thumb|300px|right|The current world headquarters of GlaxoSmithKline in [[Brentford]], [[London]]]]
In 2007 the UK had the third-highest share of global pharmaceutical R&D expenditure of any nation, with 9% of the total, behind the [[United States]] (49%) and [[Japan]] (15%).<ref name=pharmsectorbis>{{cite web|url=http://www.bis.gov.uk/policies/business-sectors/biotechnology-pharmaceuticals-and-healthcare/pharmaceutical|title=The Pharmaceutical sector in the UK|publisher=Department for Business, Innovation & Skills|accessdate=1 November 2010}}</ref><ref>{{cite web|url=http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/@ps/documents/digitalasset/dh_113133.pdf|title=Ministerial Industry Strategy Group - Pharmaceutical Industry: Competitiveness and Performance Indicators|publisher=Department of Health|accessdate=1 November 2010}}</ref> The UK has the largest pharmaceutical R&D expenditure of any European nation, accounting for 23% of the total; followed by [[France]] (20%), [[Germany]] (19%), and [[Switzerland]] (11%).<ref name=pharmsectorbis/>

{| class="wikitable"
|+ Top 25 UK investors in pharmaceuticals & biotechnology R&D - 2009/10<ref>{{cite web|url=http://webarchive.nationalarchives.gov.uk/20101208170217/http://www.innovation.gov.uk/rd_scoreboard/downloads/2010_RD_Scoreboard_data.pdf|title=The Top 1,000 UK and 1,000 Global Companies by R&D Investment|publisher=Department for Business, Innovation and Skills|accessdate=22 February 2011}}</ref> 
|- style="background:#efefef;"
|  style="width:50px; text-align:left;"| 
|  style="width:210px; text-align:left;"| '''Company<sup>a</sup>'''
|  style="width:100px; text-align:left;"| '''R&D spending<sup>b</sup> (£m)'''
|-
|  style="width:50px; text-align:left;"| 1
|  style="width:210px; text-align:left;"| [[GlaxoSmithKline]]
|  style="width:100px; text-align:left;"| 3,629.00
|-
|  style="width:50px; text-align:left;"| 2
|  style="width:210px; text-align:left;"| [[AstraZeneca]]
|  style="width:100px; text-align:left;"| 2,745.68
|-
|  style="width:50px; text-align:left;"| 3
|  style="width:210px; text-align:left;"| [[Shire plc|Shire]]  	
|  style="width:100px; text-align:left;"| 346.71
|-
|  style="width:50px; text-align:left;"| 4
|  style="width:210px; text-align:left;"| ''[[Pfizer UK]]''  	
|  style="width:100px; text-align:left;"| 325.66
|-
|  style="width:50px; text-align:left;"| 5
|  style="width:210px; text-align:left;"| ''[[Hoffmann–La Roche|Roche Products]]''	 	
|  style="width:100px; text-align:left;"| 208.44
|-
|  style="width:50px; text-align:left;"| 6
|  style="width:210px; text-align:left;"| ''[[Eisai (company)|Eisai Europe]]'' 	
|  style="width:100px; text-align:left;"| 151.13
|-
|  style="width:50px; text-align:left;"| 7
|  style="width:210px; text-align:left;"| ''[[Eli Lilly and Company]]''  	
|  style="width:100px; text-align:left;"| 130.21
|-
|  style="width:50px; text-align:left;"| 8
|  style="width:210px; text-align:left;"| ''[[Amgen]]''  	
|  style="width:100px; text-align:left;"| 127.06
|-
|  style="width:50px; text-align:left;"| 9
|  style="width:210px; text-align:left;"| ''[[Merial]]''  	
|  style="width:100px; text-align:left;"| 102.42
|-
|  style="width:50px; text-align:left;"| 10
|  style="width:210px; text-align:left;"| ''[[Novartis|Novartis Pharmaceuticals]]''	
|  style="width:100px; text-align:left;"| 90.27
|-
|  style="width:50px; text-align:left;"| 11
|  style="width:210px; text-align:left;"| ''[[Wyeth|John Wyeth & Brother]]''
|  style="width:100px; text-align:left;"| 60.33
|-
|  style="width:50px; text-align:left;"| 12
|  style="width:210px; text-align:left;"| ''[[Bristol-Myers Squibb]]''
|  style="width:100px; text-align:left;"| 55.49
|-
|  style="width:50px; text-align:left;"| 13
|  style="width:210px; text-align:left;"| ''[[Janssen-Cilag]]''  	
|  style="width:100px; text-align:left;"| 54.37
|-
|  style="width:50px; text-align:left;"| 14
|  style="width:210px; text-align:left;"| ''PowderMed''  	
|  style="width:100px; text-align:left;"| 45.57
|-
|  style="width:50px; text-align:left;"| 15
|  style="width:210px; text-align:left;"| ''[[Sanofi-Aventis|Aventis Pharma]]''	 	
|  style="width:100px; text-align:left;"| 44.92
|-
|  style="width:50px; text-align:left;"| 16
|  style="width:210px; text-align:left;"| ''[[Allergan]]'' 	
|  style="width:100px; text-align:left;"| 37.40
|-
|  style="width:50px; text-align:left;"| 17
|  style="width:210px; text-align:left;"| ''[[Organon International|Organon Laboratories]]''  	
|  style="width:100px; text-align:left;"| 36.78
|-
|  style="width:50px; text-align:left;"| 18
|  style="width:210px; text-align:left;"| [[Vectura Group|Vectura]]  	
|  style="width:100px; text-align:left;"| 36.40
|-
|  style="width:50px; text-align:left;"| 19
|  style="width:210px; text-align:left;"| Antisoma  	
|  style="width:100px; text-align:left;"| 35.77
|-
|  style="width:50px; text-align:left;"| 20
|  style="width:210px; text-align:left;"| ''[[Boehringer Ingelheim]]''	
|  style="width:100px; text-align:left;"| 29.29
|-
|  style="width:50px; text-align:left;"| 21
|  style="width:210px; text-align:left;"| [[Genus plc|Genus]]
|  style="width:100px; text-align:left;"| 28.60
|-
|  style="width:50px; text-align:left;"| 22
|  style="width:210px; text-align:left;"| [[BTG]]
|  style="width:100px; text-align:left;"| 27.00
|-
|  style="width:50px; text-align:left;"| 23
|  style="width:210px; text-align:left;"| ''[[Servier|Servier R&D]]''  	
|  style="width:100px; text-align:left;"| 25.10
|-
|  style="width:50px; text-align:left;"| 24
|  style="width:210px; text-align:left;"| ''[[Ipsen|Ipsen Developments]]''  	
|  style="width:100px; text-align:left;"| 23.97
|-
|  style="width:50px; text-align:left;"| 25
|  style="width:210px; text-align:left;"| [[Renovo plc|Renovo]]	 	
|  style="width:100px; text-align:left;"| 18.07
|}

<small>'''Notes:'''

<sup>a</sup> Italicised company name: ultimate parent is not UK-based<br /> 
<sup>b</sup> Where parent company is UK-based: worldwide R&D spending; other companies: R&D spending in UK only<br /></small>

==Regulation==
{{Expand section|year=2011|date=May 2011}}

The [[Medicines and Healthcare products Regulatory Agency]] (MHRA) is the UK government agency which is responsible for ensuring that medicines and medical devices work and are acceptably safe.<ref>{{cite web|url=http://www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/42/42.pdf|title=The Influence of the Pharmaceutical Industry - Fourth Report of Session 2004–05|publisher=United Kingdom Parliament|accessdate=26 May 2011}}</ref>

==See also==
* [[Association of the British Pharmaceutical Industry]]
* ''[[Bad Pharma]]'' (2012) by [[Ben Goldacre]]
* [[List of pharmaceutical manufacturers in the United Kingdom]]
* [[List of pharmacy organizations in the United Kingdom]]

==References==
{{Reflist|2}}

==Further reading==
*A. Duckworth, 'Rise of the pharmaceutical industry', ''Chemist and Druggist'', 172, 1959, pp 127–39
*C. A. Hill, 'The changing foundations of pharmaceutical manufacturing', ''Pharmaceutical Journal'', 134, 1935, pp 533–5
*J. Liebenau, 'The rise of the British pharmaceutical industry', ''British Medical Journal'', 301, 1990, pp 724–33
*C. J. Thomas, 'The pharmaceutical industry', in D. Burn (ed) ''The Structure of British Industry - Volume II'' (Cambridge University Press, 1958), pp 331–75
*{{cite journal
| last = Cope
| first = Zachary
| authorlink = Zachary Cope
| date = 5 February 1955
| title = Allen and Hanburys, 1715–1954
| journal = [[British Medical Journal]]
| volume = 1
| issue = 4909
| pages = 337
| issn = 0959-8138
| doi = 10.1136/bmj.1.4909.337-b
| pmid = 
| pmc = 2060881
}}

==External links==
*[http://www.abpi.org.uk/Pages/default.aspx Association of the British Pharmaceutical Industry]

{{Pharmaceutical industry in the United Kingdom}}
{{Navboxes|list1=
{{Pharmaceutical industry by country}}
{{Economy of the United Kingdom}}
{{Science and technology in the United Kingdom}}
}}

[[Category:Pharmaceutical industry in the United Kingdom| ]]